Health ❯ Healthcare ❯ Clinical Research

Patient Outcomes

Survival Rates Quality of Life Adverse Events Personalized Medicine Survival Analysis Referral Systems Precision Medicine Long-term Monitoring Family Guidance Misdiagnosis

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

Linked to dual GLP‑1/GIP targeting, tirzepatide showed larger average weight loss in trials with uncertain post‑treatment durability.

Apnimed Pill Cuts Sleep Apnea Events in Phase 3 as Company Seeks FDA Approval

Study Finds 11 Cancers Rising in Under-50s in England, With Obesity a Partial Driver

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

NEJM Publication Confirms Phase 3 Win for Brepocitinib in Dermatomyositis

Milan’s Besta Hospital Deploys Rare Exablate Prime to Speed MRI‑Guided Brain Ultrasound

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

BIOPREVENT, a Biomarker‑AI Tool, Predicts Post‑Transplant cGVHD and Mortality Months Early

Kyverna CAR-T Delivers Positive Phase 2 Topline in Stiff Person Syndrome as Shares Jump

UC San Diego Releases Public GNPS Drug Library to Identify Drug Exposure From Patient Samples

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Oral PCSK9 Pill Enlicitide Cuts LDL Up to 60% in Phase 3 Trial

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Orchestra BioMed Starts U.S. Virtue Coronary Balloon Trial as Terumo Reworks Deal With $30M Support

Study Links Sedating Antihistamine Prescribing to Higher Delirium Risk in Older Hospital Patients

Retinal Implant Helps Most Patients With Advanced Macular Degeneration Read Again, NEJM Study Finds

Tumor CRATERs Flag T-Cell Killing Hotspots and Track With Immunotherapy Response

Music Therapy Linked to Lower Heart Rate and Blood Pressure in Cardiac ICU Trial

VA Study Links Nicotinamide to Lower Skin Cancer Risk, Strongest After First Diagnosis

ATyr’s Sarcoidosis Drug Fails Phase 3 Goal, Shares Plunge Over 80%